循环酶相关蛋白2基因传递:一种潜在的多目标方法,用于预防阿尔茨海默病中突触衰竭
Ramona Stringhi1, Silvia Pelucchi1, Laura D'Andrea1
1Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti," Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.
Molecular therapy : the journal of the American Society of Gene Therapy
|December 13, 2025
概括
在阿尔茨海默氏症 (AD) 模型中过度表达环酶相关蛋白2 (CAP2) 通过维持突触可塑性和认知功能来预防突触失败,抵消粉样β毒性.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默氏病 (AD) 涉及与动因细胞骨变化相关的突触失败.
- 粉样蛋白-β (Aβ) 寡合物诱导可菲林-动因棒,导致突触损失.
- 循环酶相关蛋白2 (CAP2) 调节了科菲林的活性,在AD中被下调.
研究的目的:
- 在AD小鼠模型中研究CAP2过度表达对Aβ诱导的突触功能障碍的神经保护作用.
- 为了确定是否升高的CAP2水平可以保持突触完整性和认知功能.
主要方法:
- 腺相关病毒9型血清 (AAV) 基因传递用于APP/PS1小鼠中的CAP2过度表达.
- 小鼠接受了AAV-CAP2或控制AAV的立体注射,从无症状阶段开始.
- 评估了突触功能,cofilin-actin棒的形成,tau病理和认知表现.
主要成果:
- CAP2过度表达保留了突触CAP2/cofilin相互作用和突触可塑性通路.
- 在APP/PS1小鼠中,认知功能维持,CAP2水平升高.
- 过度表达CAP2减少了cofilin-actin棒的形成,并减轻了tau异常.
结论:
- 在阿尔茨海默病中,CAP2上调增强神经元对Aβ突触毒性的抵抗力.
- 维持CAP2/cofilin复合体对于预防Aβ驱动的突触损失至关重要.
- CAP2作为阿尔茨海默病的治疗策略显示出前景.
相关概念视频
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


